HUTCHMED Presents Clinical Data for Multiple Cancer Therapies at Major Oncology Conferences
核心洞察
HUTCHMED will present updated clinical data for savolitinib, a selective MET tyrosine kinase inhibitor, at the 2025 World Conference on Lung Cancer, including results from SACHI, SAVANNAH, and Phase IIIb studies in non-small cell lung cancer patients.
The company will showcase first-in-human Phase I data for HMPL-653, a novel CSF-1R (搜索) inhibitor for tenosynovial giant cell tumor, at the Chinese Society of Clinical Oncology Annual Meeting 2025.
Multiple investigator-initiated studies will be presented featuring fruquintinib and surufatinib combination therapies across various cancer types including colorectal, pancreatic, and biliary tract cancers.
HUTCHMED announced that new and updated clinical data from several of its cancer therapy compounds will be presented at two major oncology conferences in September 2025: the World Conference on Lung Cancer (WCLC) in Barcelona, Spain, and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting in Jinan, China.
Savolitinib Data Highlights at WCLC 2025
The company will present updated analyses from savolitinib's SACHI, SAVANNAH, and Phase IIIb confirmatory studies in non-small cell lung cancer (NSCLC) patients. Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca.
Key presentations include biomarker concordance and acquired resistance data from the SAVANNAH study in patients with EGFRm MET-overexpressing and/or amplified NSCLC, presented by Christina Baik from the University of Washington and Fred Hutchinson Cancer Center. Additional data will cover efficacy and safety of savolitinib in advanced or metastatic METex14 NSCLC patients with or without prior immunotherapy, and frontline treatment duration insights from the SACHI study in MET-amplified NSCLC after third-generation EGFR (搜索)-TKI failure.
Patient-reported outcomes from the SAVANNAH study examining osimertinib plus savolitinib in EGFRm advanced NSCLC with MET overexpression and/or amplification post-progression on osimertinib will also be presented.
Novel CSF-1R Inhibitor Data at CSCO 2025
For the first time, HUTCHMED will present clinical data of HMPL-653, a novel, selective and potent CSF-1R (搜索) inhibitor, from a first-in-human Phase I study in patients with tenosynovial giant cell tumor in China. This presentation will be delivered by Xiaohui Niu during an oral session on September 12, 2025.
Extensive Combination Therapy Research
Multiple investigator-initiated studies will showcase fruquintinib and surufatinib in various combination therapies across different cancer types. Notable presentations include fruquintinib plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma, and fruquintinib combined with camrelizumab, paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma.
Surufatinib combination studies will feature treatments for extensive-stage small-cell lung cancer, advanced biliary tract cancer, unresectable advanced pancreatic cancer, and neuroendocrine tumors. These studies demonstrate the versatility of HUTCHMED's compounds across multiple oncology indications.
Company Profile and Pipeline
HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has focused on bringing drug candidates from in-house discovery to patients worldwide, with its first three medicines marketed in China and the first also approved in the US, Europe and Japan.
The presentations at both conferences underscore HUTCHMED's commitment to advancing multiple therapeutic approaches across various cancer types, with data spanning from early-phase studies of novel targets to confirmatory studies of established compounds in partnership with major pharmaceutical companies.